Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis: A pooled analysis of the Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 3 and 4 (ISAR-DESIRE 3 and

[1]  C. Hengstenberg,et al.  Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial. , 2017, JACC. Cardiovascular interventions.

[2]  B. Levkau,et al.  SeQuent Please vs. Pantera Lux drug coated balloon angioplasty in real life: Results from the Düsseldorf DCB registry. , 2017, International journal of cardiology.

[3]  Jiyan Chen,et al.  Two‐year results and subgroup analyses of the PEPCAD China in‐stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug‐eluting stent in‐stent restenosis , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[4]  A. Kastrati,et al.  Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis , 2015, The Lancet.

[5]  H. Schunkert,et al.  Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial. , 2015, JACC. Cardiovascular interventions.

[6]  Helmut Baumgartner,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7]  Fernando Alfonso,et al.  Current treatment of in-stent restenosis. , 2014, Journal of the American College of Cardiology.

[8]  M. Joner,et al.  Drug-coated balloon therapy in coronary and peripheral artery disease , 2014, Nature Reviews Cardiology.

[9]  A. Kastrati,et al.  Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial , 2013, The Lancet.

[10]  J. Brachmann,et al.  A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. , 2012, Journal of the American College of Cardiology.

[11]  M. Joner,et al.  Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[12]  M. Joner,et al.  Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis , 2011, Thrombosis and Haemostasis.

[13]  T. Maruo,et al.  Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. , 2011, JACC. Cardiovascular interventions.

[14]  G. Stone,et al.  The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "oculostenotic" reintervention in patients with intermediate lesions. , 2010, JACC. Cardiovascular interventions.

[15]  A. Kastrati,et al.  Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. , 2009, European heart journal.

[16]  Ralf Degenhardt,et al.  Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis , 2009, Circulation.

[17]  M. Böhm,et al.  Hotline update of clinical trials and registries presented at the German Cardiac Society meeting 2008 , 2008, Clinical Research in Cardiology.

[18]  M. Böhm,et al.  Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. , 2006, Clinical research in cardiology : official journal of the German Cardiac Society.

[19]  S. Pocock,et al.  Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. , 2008, Journal of the American College of Cardiology.

[20]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[21]  S. Grossmann,et al.  Inhibition of Restenosis in Stented Porcine Coronary Arteries: Uptake of Paclitaxel From Angiographic Contrast Media , 2004, Investigative radiology.

[22]  M. Böhm,et al.  Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. , 2003, Journal of the American College of Cardiology.

[23]  M. Böhm,et al.  Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. , 2003, European heart journal.

[24]  G. Stone,et al.  Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.

[25]  D. Baim,et al.  A Predictive Method for Estimating the Late Angiographic Results of Coronary Intervention Despite Incomplete Ascertainment , 1993, Circulation.